Ikena Oncology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 43
- Market Cap
- $83.7M
- Website
- http://www.ikenaoncology.com
- Introduction
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
- Conditions
- Non-Small Cell Lung CarcinomaGliomas, MalignantSolid Tumor, AdultColorectal CancerPancreatic CancerMalignant MelanomaRas (Kras or Nras) Gene MutationCRAF Gene MutationThyroid CarcinomaBRAF Gene Mutation
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Ikena Oncology
- Target Recruit Count
- 150
- Registration Number
- NCT06270082
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Johns Hopkins University of Medicine Sidney Kimmel Comprehensive Care Center, Washington, District of Columbia, United States
🇺🇸University of Miami, Miami, Florida, United States
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
- Conditions
- Head Cancer NeckNeck CancerHead and Neck CancerNeck CarcinomaHead and Neck Squamous Cell CarcinomaHead Cancer
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Ikena Oncology
- Registration Number
- NCT05472506
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumors, AdultSolid TumorMalignant Pleural Mesothelioma (MPM)Epithelioid Hemangioendothelioma (EHE)NF2 Deficient MesotheliomaOther NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion GenesNF2 DeficiencyYAP1 or TAZ Gene Fusions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Ikena Oncology
- Target Recruit Count
- 67
- Registration Number
- NCT05228015
- Locations
- 🇦🇺
Peninsula South Eastern Haematology and Oncology Group (PASO Medical), Frankston, Victoria, Australia
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of PY314 in Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorTriple Negative Breast CancerLung AdenocarcinomaRenal Cell CarcinomaOvarian CancerGynecologic CancerBreast CancerColorectal CancerHormone Receptor/Growth Factor Receptor-Negative Breast Cancer
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Ikena Oncology
- Target Recruit Count
- 86
- Registration Number
- NCT04691375
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Stanford Hospital and Clinics, Palo Alto, California, United States
🇺🇸City of Hope - Comprehensive Cancer Center, Duarte, California, United States
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- Conditions
- Gastric AdenocarcinomaColorectal CancerPancreatic CancerAdvanced Solid TumorGynecologic CancerBreast CancerLung AdenocarcinomaHead and Neck Cancer
- Interventions
- Drug: PY159 Single agent dose level 4Drug: PY159 Single agent dose level 7Drug: PY159 Single agent dose level 2Drug: PY159 Single agent dose level 3Drug: PY159/Pembrolizumab Combination dose expansion cohort 6Drug: PY159 Single agent dose level 1Drug: PY159 Single agent dose expansion cohortDrug: PY159/Pembrolizumab Combination dose expansion cohort 2Drug: PY159/Pembrolizumab Combination dose expansion cohort 3Drug: PY159 Single agent dose level 5Drug: PY159 Single agent dose level 6Drug: PY159/Pembrolizumab Combination dose level 3Drug: PY159/Pembrolizumab Combination dose level 4Drug: PY159/Pembrolizumab Combination dose expansion cohort 1Drug: PY159/Pembrolizumab Combination dose expansion cohort 4Drug: PY159/Pembrolizumab Combination dose expansion cohort 5Drug: PY159/Pembrolizumab Combination dose level 1Drug: PY159/Pembrolizumab Combination dose level 2
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Ikena Oncology
- Target Recruit Count
- 127
- Registration Number
- NCT04682431
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Parkside Cancer Center, Santa Monica, California, United States
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
- Conditions
- Solid TumorMetastatic CancerAdvanced CancerUrothelial CarcinomaNeoplasm MalignantMetastatic Bladder CancerMetastatic Urothelial CarcinomaNeoplasm, BladderBladder Urothelial CarcinomaUrothelial Carcinoma Bladder
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Ikena Oncology
- Target Recruit Count
- 78
- Registration Number
- NCT04200963
- Locations
- 🇺🇸
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Banner Health- MD Anderson Cancer Center, Gilbert, Arizona, United States